Skip to content

Emilie Tomkova

2 papers in the library · 3 citations · publishing 2025

Papers

Sort Most recent Most cited

[Treatment with psychedelics : potential benefits in Parkinson's disease].

Revue Médicale Suisse April 23, 2025 Louise Penzenstadler, Sandra Baudois, Alma Lingenberg et al.

Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their efficacy has been demonstrated in depression and anxiety, where they are particularly interesting because of their rapid and long-lasting effect. They could also be beneficial for addictions, post-traumatic stress, and obsessive-compulsive disorder. This...

DOI: 10.53738/REVMED.2025.21.915.47180 (opens in new tab) Full text (opens in new tab) Psychedelics Parkinsons-disease Mental-health Brain-research

Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.

Journal of Parkinson's disease March 1, 2025 Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé et al. 3 citations

BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant...

DOI: 10.1177/1877718x241312604 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Parkinsons treatment Mental health outcomes Patient resilience +4